IMG Pharma to Acquire Matsumoto Pharmaceutical in Japan

IMG Pharmaceutical Co., Ltd.,  a majority-owned subsidiary of IMG Japan, the Group's holding company, announced that it has entered into a definitive agreement to acquire Matsumoto Pharmaceutical Co., Ltd., a Japanese pharmaceutical manufacturer.

IMG Medical Group operates an integrated healthcare platform across Asia, providing structured clinical services and long-term health management across the full lifecycle of care—from life creation and optimization to preservation. Within this framework, IMG Pharma serves as the Group's pharmaceutical and product platform, translating clinical needs and medical pathways into standardized, scalable pharmaceutical and health products.

This integration combines IMG Pharma's biopharmaceutical and translational capabilities with Matsumoto Pharmaceutical's manufacturing foundation and OTC product system, forming a multi-layered product capability structure. It is expected to support the development of a scalable pharmaceutical and health product platform addressing long-term health management needs.

"This agreement is not only an important step in strengthening IMG Pharma's pharmaceutical and product platform, but also reflects our broader approach to building a structured system that connects scientific innovation with real-world healthcare applications," said Yuki Sakurai, CEO of IMG Pharma.

"By integrating Kobe-based R&D and translational capabilities with Matsumoto Pharmaceutical's established manufacturing and OTC system, we are creating a more scalable pathway from clinical care to product-based health solutions, with a continued focus on long-term health management."